In the current study, Loeffler, Reed, and colleagues injected mice with tumors derived from mouse breast and colon cancers with attenuated FasL-expressing Salmonella.
Following the treatment, primary tumor growth was substantially inhibited in mice with either breast or colon tumors and lung metastases were reduced in the mice with breast cancer. The anti-cancer effect appeared dependent on the presence of inflammatory cells called neutrophils.
Although toxicology and other studies are needed before the approach can be tested in human clinical trials, "these results from murine cancer models suggest that FasL-expressing [Salmonella] could offer an acceptable strategy for employing FasL and possibly other toxic cytokines for cancer therapy," the authors conclude.
Contact: Andrea Moser, email@example.com, (858) 646-3146
|Contact: Liz Savage|
Journal of the National Cancer Institute